psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
Company profile
Ticker
EYPT
Exchange
Website
CEO
Nancy Sue Lurker
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
pSivida Corp., pSivida LTD
SEC CIK
Corporate docs
Subsidiaries
EyePoint Pharmaceuticals US, Inc. • pSiMedica Limited • EyePoint Pharmaceuticals Securities Corporation • Icon Bioscience, Inc. ...
IRS number
262774444
EYPT stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
8 Mar 24
8-K
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
8-K
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
4 Mar 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
8 Dec 23
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
7 Dec 23
424B5
Prospectus supplement for primary offering
7 Dec 23
424B5
Prospectus supplement for primary offering
4 Dec 23
8-K
Other Events
4 Dec 23
8-K
Other Events
9 Nov 23
Transcripts
EYPT
Earnings call transcript
2023 Q4
7 Mar 24
EYPT
Earnings call transcript
2023 Q3
1 Nov 23
EYPT
Earnings call transcript
2023 Q2
2 Aug 23
EYPT
Earnings call transcript
2023 Q1
3 May 23
EYPT
Earnings call transcript
2022 Q4
2 Mar 23
EYPT
Earnings call transcript
2022 Q3
2 Nov 22
EYPT
Earnings call transcript
2022 Q2
3 Aug 22
EYPT
Earnings call transcript
2022 Q1
4 May 22
EYPT
Earnings call transcript
2021 Q4
3 Mar 22
EYPT
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
3
Robert Atchinson
22 Apr 24
4
Bihua Chen
22 Apr 24
4
Dario A. Paggiarino
2 Apr 24
4
Ramiro Ribeiro
4 Mar 24
3
Ramiro Ribeiro
4 Mar 24
4
Jay S. Duker
28 Feb 24
4
Jay S. Duker
22 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
4
Nancy Lurker
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 133.19 mm | 133.19 mm | 133.19 mm | 133.19 mm | 133.19 mm | 133.19 mm |
Cash burn (monthly) | 2.19 mm | (no burn) | 4.80 mm | 8.54 mm | 5.07 mm | (no burn) |
Cash used (since last report) | 15.08 mm | n/a | 33.10 mm | 58.87 mm | 34.95 mm | n/a |
Cash remaining | 118.10 mm | n/a | 100.09 mm | 74.31 mm | 98.24 mm | n/a |
Runway (months of cash) | 54.0 | n/a | 20.9 | 8.7 | 19.4 | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 187 |
Opened positions | 39 |
Closed positions | 41 |
Increased positions | 65 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 683.59 bn |
Total shares | 116.19 mm |
Total puts | 185.10 k |
Total calls | 458.60 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Bamco | 25.03 mm | $147.69 bn |
Vanguard | 12.28 mm | $72.44 bn |
BLK Blackrock | 9.84 mm | $58.08 bn |
Capital International Investors | 8.57 mm | $50.56 bn |
T. Rowe Price Investment Management | 8.29 mm | $49.28 bn |
AMP Ameriprise Financial | 5.08 mm | $29.97 bn |
BEN Franklin Resources | 4.33 mm | $25.54 bn |
D. E. Shaw & Co. | 3.90 mm | $23.02 bn |
Dimensional Fund Advisors | 2.57 mm | $15.16 bn |
MS Morgan Stanley | 2.55 mm | $15.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Cormorant Asset Management | Common Stock | Buy | Acquire P | Yes | No | 18.9 | 186,521 | 3.53 mm | 7,475,000 |
18 Apr 24 | Cormorant Asset Management | Common Stock | Buy | Acquire P | Yes | No | 17.62 | 395,244 | 6.96 mm | 7,288,479 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Payment of exercise | Dispose F | No | No | 20.67 | 7,096 | 146.67 k | 67,080 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Payment of exercise | Dispose F | No | No | 20.67 | 2,957 | 61.12 k | 74,176 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Payment of exercise | Dispose F | No | No | 20.67 | 15,493 | 320.24 k | 77,133 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Option exercise | Acquire M | No | No | 0 | 14,000 | 0.00 | 92,626 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Option exercise | Acquire M | No | No | 0 | 30,570 | 0.00 | 78,626 |
30 Mar 24 | Dario A. Paggiarino | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,834 | 0.00 | 48,056 |
30 Mar 24 | Dario A. Paggiarino | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 14,000 | 0.00 | 0 |
30 Mar 24 | Dario A. Paggiarino | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,834 | 0.00 | 0 |
News
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
23 Apr 24
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
8 Mar 24
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
8 Mar 24
EyePoint Pharmaceuticals Q4 GAAP EPS $(0.33) Beats $(0.49) Estimate, Sales $14.03M Beat $8.90M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
Press releases
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
2 Apr 24
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
27 Feb 24
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 Feb 24
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
3 Feb 24